Axsome Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $638.5 | $385.7 | $270.6 | $50.0 | — |
| Operating income | -$166.8 | -$280.6 | -$231.8 | -$179.8 | -$124.7 |
| Net income | -$183.2 | -$287.2 | -$239.2 | -$187.1 | -$130.4 |
| Balance Sheet | |||||
| Total debt | $120.0 | $180.0 | $180.0 | $95.0 | $50.0 |
| Cash Flow Statement | |||||
| Free cash flow | -$93.9 | -$128.7 | -$145.7 | -$117.2 | -$108.5 |
Shares outstanding 51.5M · Free float 63.8%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.